MYGNMyriad Genetics, Inc.
Price
-26%1YEnd-of-day closes, not the intraday tick.
Great business, demanding price
Quality strong, a flag to check, demanding price, growth steady, the market undecided.
Charts
As reported to the SEC, without any scoring.
Myriad Genetics, Inc. (MYGN) reported revenue of $191M in Q2 2027 (quarter ended Jun 30, 2026), down 11% from the same quarter a year earlier. That came with a gross margin of 67% and net loss of $43M. For the full year FY2026, revenue was $825M (−1.6% year on year) and net income −$366M. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 20, 2026On October 19, 2026, Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Laboratory Corporation of America, a Delaware corporation (“Buyer”), entered into an Asset Purchase Agreement (the “Purchase Agreement”)Material agreement entered · Form 8-K
- Oct 9, 2026On October 6, 2026, Myriad Genetics, Inc. (the “Company”) entered into a Separation Agreement and Release of Claims (the “Separation Agreement”) with Brian Donnelly, the Company’s former Chief Commercial Officer.Director or officer change · Form 8-K
- Sep 16, 2026On September 16, 2026, Myriad Genetics, Inc. (the “Company”) announced that, effective September 16, 2026, Brian Donnelly no longer serves as Chief Commercial Officer of the Company.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #16 of 21 by RyuScore